Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 404

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 404
---
 |    2,799 |     |     |    2,799 |
| Restricted stock - unvested            |     |     |        6 |     |     |        6 |
| Common stock warrants                  |     |     |        3 |     |     |        3 |
| Stock options                          |     |     |      465 |     |     |      272 |
| Total potentially dilutive shares      |     |     |    3,273 |     |     |    3,080 |

10. Stock-Based Compensation The Company uses equity-based compensation programs to provide long-term performance incentives for its employees, directors and consultants. These incentives consist primarily of stock options and restricted stock grants. F-51

LB Pharmaceuticals Inc Notes to Condensed Financial Statements (Unaudited) In January 2017, the Company’s Board of Directors approved the LB Pharmaceuticals Inc 2017 Stock Incentive Plan (“2017 Plan”). In October 2018, the Company’s Board of Directors approved the LB Pharmaceuticals Inc 2018 Stock Incentive Plan (“2018 Plan”). No additional shares will be issued under the 2017 and 2018 Plans. As of both June 30, 2025 and December 31, 2024, there were 0.01 million and 0.03 million shares outstanding under the 2017 Plan and the 2018 Plan, respectively. In August 2023, the Company’s Board of Directors approved the LB Pharmaceuticals Inc 2023 Stock Incentive Plan (“2023 Plan”). The 2023 Plan authorized the issuance of stock options or restricted stock up to 0.3 million shares of the Company’s common stock. In December 2024, the Company amended the 2023 Plan increasing the maximum aggregate number of shares that may be issued under the 2023 Plan to 0.5 million. The 2023 Plan expires in August 2033. As of June 30, 2025 and December 31, 2024, there were 0.4 million and 0.4 million shares outstanding under the 2023 Plan, respectively. As of June 30, 2025, 0.03 million shares were available for future issuance under the 2023 Plan. Stock Options The stock options granted in the six months ended June 30, 2025 (awarded on February 11, 2025) and 2024 vest based on one